Bain Capital, the Canada Pension Plan Investment Board, and Bristol Myers are doubling down on Beeline Medicines with a $126.3 million extension to the original $300 million raise.
Bristol Myers Squibb spinout Beeline Medicines is getting extra love from its existing backers and some of its management team.
Bain Capital, the Canada Pension …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of…
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
Apogee details its $10.9B AbbVie buyout, the UK launches a drug-pricing pilot, and Brii shares Phase 2b HBV vaccine data.
BridgeBio raises $1B via preferred equity from Sixth Street and KKR's HealthCare Royalty, stockpiling cash ahead of three drug…
Oblenio Bio raises $62M Series B led by Pfizer Venture Investments to advance LBL-051, a trispecific TCE targeting BCMA, CD19,…
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
